Biography
Dr Po Inglis is a highly experienced medical oncologist with extensive expertise in the management of a wide range of solid tumour malignancies. She is known for her patient-centred approach, combining evidence-based care with clear communication and compassionate support to ensure patients feel informed and confident throughout their treatment journey.
Dr Inglis is a Senior Medical Oncologist with more than 15 years’ experience across leading public and private hospitals in Queensland. She consults at the Icon Cancer Centre consultation rooms located at St Vincent’s Private Hospital Northside, with treatment provided on-site.
Alongside her private practice, Dr Inglis is a Senior Medical Oncologist at the Royal Brisbane and Women’s Hospital and The Prince Charles Hospital, where she is actively involved in multidisciplinary cancer care, clinical trials and service development.
Dr Inglis holds a Bachelor of Science from Monash University and a Bachelor of Medicine and Bachelor of Surgery from the University of Adelaide. She is a Fellow of the Royal Australasian College of Physicians and completed her advanced training in medical oncology at major Queensland tertiary hospitals.
She has held significant leadership and academic roles, including Lead Clinician for the Queensland Youth Cancer Service and Senior Lecturer at The University of Queensland. Dr Inglis has contributed extensively to oncology research as a Principal and Co-Investigator across national and international clinical trials, with numerous peer-reviewed publications and presentations.
Her clinical practice is underpinned by a strong interest in improving treatment outcomes through clinical research, precision medicine and collaboration across multidisciplinary teams.
Publications
Manavis J, Lee PL, Blumbergs PC, Lewis SB, Finnie JW, Reilly PL, Jones NR. Widespread early dendritic injury associated with loss of cortical MAP-2 immunostaining in a focal ovine head impact model. Journal of Neuroscience, 1996; 16:500–505.
Coventry BJ, Lee PL, Gibbs D, Hart DNJ. Dendritic cell density and activation status in human breast cancer: CD1a, CMRF-44, CMRF-56 and CD83 expression. British Journal of Cancer, 2002; 86:546–551.
Day BW, Stringer BW, Spanevello MD, et al. Inglis PL. ELK4 neutralisation sensitises glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. Neuro-Oncology, 2011.
Day BW, Stringer BW, Al‑Ejeh F, et al. Inglis PL. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell, 2013; 23:238–248.
Collins JT, Narayana MJ, Morris K, et al. Inglis PL. Adult medulloblastoma: feasibility and effectiveness of utilising high-dose chemotherapy with autologous stem cell rescue in newly diagnosed patients. Internal Medicine Journal, 2014; 44:209–210.